

Shankaran, Jayendri

From: Shankaran, Jayendri
Sent: Thursday, March 21, 2013 10:00 AM
To: 'essietgibsoni@niaid.nih.gov'; 'swelsch@niaid.nih.gov';
'NIAIDOPCROPRTeam@niaid.nih.gov'; 'NIAIDOPCROSPT@niaid.nih.gov';
'NIAIDDAIDSRABIND@niaid.nih.gov'; 'NIAIDOPCROCTA@niaid.nih.gov';
'ActgRSCCommunications@s-3.com'; 'Vtn.core.reg@hvtn.org';
'Inoguchi@mail.magee.edu'; 'IMPAACTOPS@S-3.com'; 'MImmelman@fhi360.org';
'kquick@fhi360.org'; 'sitereg@insight-trials.org';
'IMPAACTRegulatoryDesk@Westat.com'; 'fstrf.contacts@fstrf.org'; 'Molly@scharp.org';
'sc.clin.aff@scharp.org'; 'hyhuang@scharp.org'; 'VRC-Protocol@mail.nih.gov';
'cvilla@fhcrc.org'; 'mtnregulatory@mtnstopshiv.org'; 'jmanes@fhi360.org';
'NIAIDOPCROProPEP@mail.nih.gov'; RSC Safety Information Center; #DAIDS;
'ksmith@niaid.nih.gov'; Berko-Amoako, Sylvia; Lohse, Pia (NIH/NIAID) [E]
Cc: #DAIDSRSC Website Support
Subject: New Content on DAIDS RSC Website

Good Morning,

The following content change has been made to the DAIDS RSC website:

- **Protocol Development Information → Drug Risk List Table**
The DAIDS Risk List for the drug: Rilpivirine (Edurant) has been added to the 'DAIDS Drug List Table' (NO: 19)
Please review at: <http://rsc.tech-res.com/protocoldevelopmentinformation/DrugRiskList.aspx> .

Please contact me with questions.

Regards,

DAIDS RSC Website Maintenance
DAIDS Regulatory Support Center
Technical Resources International, Inc.
6500 Rock Spring Drive, Suite 650
Bethesda, MD 20817
Tel: 301-897-7456